Heron Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Heron Therapeutics

23/03/2023 21:01

* Heron Therapeutics Inc  HRTX.OQ  reported a quarterly
adjusted
loss of 17 cents​​ per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 28 cents per share.
    * Revenue rose 45.4% to $30.03 million from a year ago;
analysts
expected $26.90 million. 
    * Heron Therapeutics Inc's reported EPS for the quarter was
a loss
of 17 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Heron Therapeutics Inc shares had fallen by 21.2% this
quarter.
    * The company reported a quarterly loss of $19.87 million.
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $10.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 23 at 09:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.28          -0.17          Beat
 Sep. 30 2022      -0.38          -0.38          Met
 Jun. 30 2022      -0.50          -0.55          Missed
 Mar. 31 2022      -0.48          -0.63          Missed